[EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
申请人:EPIZYME INC
公开号:WO2014100730A1
公开(公告)日:2014-06-26
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.
Metal-free I<sub>2</sub>O<sub>5</sub>-mediated direct construction of sulfonamides from thiols and amines
作者:Minghui Zhu、Wei Wei、Daoshan Yang、Huanhuan Cui、Leilei Wang、Guoqing Meng、Hua Wang
DOI:10.1039/c7ob00668c
日期:——
A simple and convenient method has been developed for the construction of sulfonamides via I2O5-mediated sulfonylation of amines with arylthiols. The present protocol provides an attractive approach to sulfonamides in moderate to good yields from readily accessible and easy to handle starting materials under mild and metal-free conditions.
One-Pot Sulfonamide Synthesis Exploiting the Palladium-Catalyzed Sulfination of Aryl Iodides
作者:Michael Willis、Emmanuel Flegeau、Jack Harrison
DOI:10.1055/s-0035-1560578
日期:——
prepared from aryl iodides and the sulfurdioxidesurrogateDABSO, under the action of a palladium(0) catalyst, are transformed in a one-pot process to a variety of functionalized sulfonamides. The sulfinate to sulfonamide transformation is achieved by simple treatment with an aqueous solution of the relevant amine and sodium hypochlorite (bleach). A broad range of amines, including anilines, and amino
[EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
申请人:EPIZYME INC
公开号:WO2014100734A1
公开(公告)日:2014-06-26
Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.